Smooth Muscle Contraction Mechanism: Calcium-Calmodulin-MLCK Pathway

Smooth muscle contraction differs fundamentally from skeletal muscle in its calcium source, regulatory proteins, and phosphorylation-dependent mechanism.

Stepwise Mechanism

1. Stimulus & Calcium Entry
   • Agonist (norepinephrine, angiotensin II, endothelin) → GPCR → PLC → IP₃ + DAG.
   • IP₃ → SR Ca²⁺ release (minor in vascular SM).
   • Primary: Voltage-gated (L-type) and receptor-operated Ca²⁺ channels (ROCC) → extracellular Ca²⁺ influx.
   • Also: Store-operated Ca²⁺ entry (SOCE) via STIM/Orai.
2. Calcium-Calmodulin Complex Formation
   • Ca²⁺ binds calmodulin (CaM) (4 Ca²⁺/CaM).
   • Ca²⁺-CaM undergoes conformational change.
3. MLCK Activation
   • Ca²⁺-CaM binds and activates myosin light chain kinase (MLCK).
   • MLCK phosphorylates serine-19 on myosin light chain (MLC₂₀).
4. Cross-Bridge Cycling
   • Phospho-MLC → conformational change in myosin head → binds actin.
   • ATP hydrolysis → power stroke → filament sliding → contraction.
5. Relaxation
   • MLC phosphatase (MLCP) dephosphorylates MLC → relaxation.
   • Regulated by: RhoA/ROCK (inhibits MLCP → Ca²⁺ sensitization), PKG/PKA (activate MLCP → Ca²⁺ desensitization), CPI-17, telokin.

Key Differences from Skeletal Muscle

Feature	Smooth Muscle	Skeletal Muscle
Ca²⁺ Source	Primarily extracellular (L-type, ROCC, SOCE)	Sarcoplasmic reticulum (RyR1)
Ca²⁺ Sensor	Calmodulin	Troponin C (on thin filament)
Regulatory Target	MLC phosphorylation (thick filament)	Troponin-tropomyosin (thin filament)
Kinase	MLCK	None (Ca²⁺ directly moves tropomyosin)
Contraction Speed	Slow, sustained (tonic)	Fast, phasic
Energy Efficiency	High (latch state: dephosphorylated but attached cross-bridges)	Lower
Regulation	Multifactorial: neural, hormonal, mechanical, metabolic	Somatic motor neuron (ACh → EPP → AP)

Latch State (Unique to Smooth Muscle)

Dephosphorylated myosin remains attached to actin ("latch bridges"), maintaining force with minimal ATP consumption. Critical for sustained vascular tone.

Clinical Relevance

• Vasodilators: NO → cGMP → PKG → MLCP activation; CCBs block Ca²⁺ entry.
• Bronchodilators: β₂-agonists → cAMP → PKA → MLCP activation.
• Uterine relaxants: Magnesium sulfate, nifedipine, β-agonists (tocolysis).

Understanding this pathway underpins treatment of hypertension, asthma, preterm labor, and erectile dysfunction.